Assertio Stock Forecast, Price & News

Assertio (NASDAQ:ASRT) Frequently Asked Questions

Is Assertio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Assertio stock.
View analyst ratings for Assertio or view top-rated stocks.

How has Assertio's stock price been impacted by Coronavirus (COVID-19)?

Assertio's stock was trading at $0.9301 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ASRT shares have increased by 59.1% and is now trading at $1.48.
View which stocks have been most impacted by COVID-19.

Are investors shorting Assertio?

Assertio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,250,000 shares, an increase of 23.8% from the October 31st total of 1,010,000 shares. Based on an average trading volume of 953,700 shares, the short-interest ratio is currently 1.3 days. Approximately 3.0% of the company's stock are short sold.
View Assertio's Short Interest.

When is Assertio's next earnings date?

Assertio is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Assertio.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. Assertio had a negative trailing twelve-month return on equity of 34.57% and a negative net margin of 28.04%. During the same period last year, the business earned ($0.36) earnings per share.
View Assertio's earnings history.

Who are Assertio's key executives?

Assertio's management team includes the following people:

• Daniel A. Peisert, President, Chief Executive Officer & Director (LinkedIn Profile)
• Paul Schwichtenberg, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
• Ajay Patel, Chief Accounting Officer & Senior Vice President (LinkedIn Profile)
• Megan C. Timmins, Secretary, Senior Vice President & General Counsel
• Max Nemmers, Head-Investor Relations & Administration

Who are some of Assertio's key competitors?

Some companies that are related to Assertio include Syros Pharmaceuticals (SYRS), UroGen Pharma (URGN), PLx Pharma (PLXP), XOMA (XOMA), Aquestive Therapeutics (AQST), CTI BioPharma (CTIC), Pieris Pharmaceuticals (PIRS), GX Acquisition (GXGX), DURECT (DRRX), Connect Biopharma (CNTB), Citius Pharmaceuticals (CTXR), TherapeuticsMD (TXMD), CymaBay Therapeutics (CBAY), Wave Life Sciences (WVE) and Athersys (ATHX).
View all of ASRT's competitors.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

What is Assertio's stock symbol?

Assertio trades on the NASDAQ under the ticker symbol "ASRT."

Who are Assertio's major shareholders?

Assertio's stock is owned by a variety of retail and institutional investors. Top institutional investors include CI Investments Inc. (1.13%), Geode Capital Management LLC (0.77%), TSP Capital Management Group LLC (0.60%), Perritt Capital Management Inc. (0.49%), Millennium Management LLC (0.16%) and Morgan Stanley (0.16%). Company insiders that own Assertio stock include Ajay Patel, Daniel A Peisert, Group LP Cr, Karen A Dawes and Paul Schwichtenberg.
View institutional ownership trends for Assertio.

Which major investors are selling Assertio stock?

ASRT stock was sold by a variety of institutional investors in the last quarter, including CI Investments Inc., and HAP Trading LLC.
View insider buying and selling activity for Assertio or view top insider-selling stocks.

Which major investors are buying Assertio stock?

ASRT stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Perritt Capital Management Inc., Millennium Management LLC, Geode Capital Management LLC, Morgan Stanley, and Citadel Advisors LLC. Company insiders that have bought Assertio stock in the last two years include Ajay Patel, Daniel A Peisert, and Paul Schwichtenberg.
View insider buying and selling activity for Assertio or or view top insider-buying stocks.

How do I buy shares of Assertio?

Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assertio's stock price today?

One share of ASRT stock can currently be purchased for approximately $1.48.

How much money does Assertio make?

Assertio has a market capitalization of $66.06 million and generates $106.28 million in revenue each year. The company earns $-28.14 million in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Assertio have?

Assertio employs 27 workers across the globe.

What is Assertio's official website?

The official website for Assertio is www.assertiotx.com.

Where are Assertio's headquarters?

Assertio is headquartered at 100 South Saunders Road Suite 300, Lake Forest IL, 60045.

How can I contact Assertio?

Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The company can be reached via phone at (224) 419-7106, via email at [email protected], or via fax at 510-744-8001.